Navigation Links
Phase III study shows everolimus delays tumor progression in hard-to-treat neuroendocrine tumors

The results of a large Phase-III clinical trial have shown that the drug everolimus delays tumor progression in patients with a hard-to-treat group of rare cancers that affect particular hormone-producing cells.

At the 35th Congress of the European Society for Medical Oncology (ESMO), Dr Marianne Pavel from Charit University in Berlin, Germany reported that everolimus improved progression-free survival by 5.1 months in patients with advanced neuroendocrine tumors.

Neuroendocrine tumors are slow-growing malignancies that originate from cells of the body's neuroendocrine system. These cells are found throughout the body in organs such as the gastrointestinal tract and the lungs. The tumors are mostly non-responsive to chemotherapy drugs. They affect less than five people in 100,000, and until now there have been few treatment options for inhibition of tumor growth.

In the new RADIANT-2 trial, researchers in several European countries and the USA treated 429 patients with progressing, well- or moderately-differentiated advanced neuroendocrine tumors with either everolimus plus a somatostatin analog called octreotide LAR, or placebo plus octreotide LAR.

All patients had a history of 'carcinoid' symptoms, meaning the tumors have been secreting excessive levels of amines, especially serotonin, leading to symptoms such as flushing and diarrhea. The tumor originated in the small intestine in about 50% of patients.

Overall, the median progression-free survival for patients given everolimus plus octreotide LAR was 16.4 months, significantly longer than the median 11.3 months for placebo plus octreotide LAR, Dr Pavel reported.

"This is the first Phase-III trial of the combination therapy with octreotide LAR and everolimus and it is the largest trial that has ever been done in this type of neuroendocrine tumors," Dr Pavel said. "When we designed the study, we tested for an improvement of at least 4.5 months compared to octreotide LAR and were pleased with the resulting 5.1 month difference."

Currently, treatment options for neuroendocrine tumors are limited. Chemotherapy is only effective in neuroendocrine tumors affecting the pancreas. For tumors that originate in other organs, treatments include somatostatin analogs that control symptoms related to over-secretion of compounds such as serotonin. Interferon-alpha is also approved for these types of neuroendocrine tumors which are also referred to as carcinoid tumors. A placebo-controlled trial recently demonstrated that octreotide LAR has anti-tumor effects in neuroendocrine tumors of the small intestine.

"Since chemotherapeutic drugs are not effective in this type of neuroendocrine tumor patient, we now have for the first time a drug that has been studied in a Phase-III trial that offers antitumor efficacy in addition to the currently available agents, somatostatin analogs and interferon," Dr Pavel said.

"I think the drug will be further explored in this type of tumor. It seems important to identify patients that may benefit most from the combination of everolimus and octreotide LAR compared to octreotide LAR alone."

Dr Roberto Labianca from Ospedali Riuniti di Bergamo, Italy, commented: "This large Phase III trial in a rare tumor shows that everolimus is able to increase the efficacy of octreotide LAR, at the present time the standard treatment for advanced neuroendocrine tumors."

"This trial should be considered a practice-changing achievement but it is essential that selection criteria are refined in order to identify the population more likely to respond to this approach," Dr Labianca said. "Further trials in this field are needed, preferably in the frame of a large cooperative collaboration."


Contact: Vanessa Pavinato
European Society for Medical Oncology

Related medicine news :

1. Front-of-package symbols and systems: IOM phase 1 report
2. Vaccine extends glioblastoma patients survival in phase II trial
3. Operation Unified Response: 3 phases of disaster care in Haiti
4. Aeras and Crucell announce Phase II clinical trial start in Kenya
5. Sickle cell treatment developed at LA BioMed enters Phase 3 clinical trial
6. Mass. General Hospital, Iacocca Foundation announce completion of Phase I diabetes trial
7. Late-stage ovarian cancer shows promise in 2-drug phase I trial
8. Late-stage ovarian cancer shows promise in two-drug phase I trial
9. Accumed Research Associates Expands Capabilities In Phase I and Bioequivalence Clinical Trials
10. Phase II study of an oral therapy for Gaucher disease yields positive results
11. New phase II study supports potential of gs-9450 as new treatment option for steatohepatitis
Post Your Comments:
(Date:6/25/2016)... ... June 25, 2016 , ... Experts from the ... AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the Hynes Convention Center in ... topics including advance care planning, healthcare costs and patient and family engagement. , ...
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand gesture animations, FCPX ... Austin - CEO of Pixel Film Studios. , ProHand Cartoon’s package transforms over ... Cut Pro X . Simply select a ProHand generator and drag it above media ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson has dedicated ... has implemented orthobiologic procedures as a method for treating his patients. The procedure ... doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons use to ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published June ... with. The article goes on to state that individuals are now more comfortable seeking ... common operations such as calf and cheek reduction. The Los Angeles area medical group, ...
(Date:6/24/2016)... ... ... was in a crisis. Her son James, eight, was out of control. Prone to extreme ... “When something upset him, he couldn’t control his emotions,” remembers Marcy. “If there was ... other children and say he was going to kill them. If we were driving ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... -- Research and Markets has announced the addition ... - Forecast to 2022" report to their offering. ... to date financial data derived from varied research sources to ... potential impact on the market during the next five years, ... of sub markets, regional and country level analysis. The report ...
(Date:6/23/2016)... Research and Markets has announced the ... report to their offering. ... favourable commercial environment for MedImmune to enter. The US ageing ... serve to drive considerable growth for effective anti-influenza medications. The ... sales considerably, but development is still in its infancy. ...
(Date:6/23/2016)... , June 23, 2016 , ... on Thursday, July 7, 2016 , , , , LOCATION: ... , , , , EXPERT PANELISTS:  , , , ... Senior Industry Analyst, Christi Bird; Senior Industry Analyst, Divyaa Ravishankar and ... The global pharmaceutical industry is witnessing an exceptional era. ...
Breaking Medicine Technology: